221 related articles for article (PubMed ID: 19023373)
21. Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven.
Lucas GM
J Antimicrob Chemother; 2005 Apr; 55(4):413-6. PubMed ID: 15722389
[TBL] [Abstract][Full Text] [Related]
22. Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients.
Wirden M; Lambert-Niclot S; Marcelin AG; Schneider L; Ait-Mohand H; Brunet C; Angleraud F; Amard S; Katlama C; Calvez V
AIDS; 2009 Jan; 23(1):95-9. PubMed ID: 19050391
[TBL] [Abstract][Full Text] [Related]
23. [HIV resistance testing. Introduction of a new technique].
Dragsted UB; Benfield TL
Ugeskr Laeger; 2002 Apr; 164(17):2263-7. PubMed ID: 11989174
[TBL] [Abstract][Full Text] [Related]
24. HIV drug resistance threshold survey using specimens from voluntary counselling and testing sites in Hanoi, Vietnam.
Nguyen HT; Duc NB; Shrivastava R; Tran TH; Nguyen TA; Thang PH; McNicholl JM; Leelawiwat W; Chonwattana W; Sidibe K; Fujita M; Luu CM; Kakkar R; Bennett DE; Kaplan J; Cosimi L; Wolfe MI
Antivir Ther; 2008; 13 Suppl 2():115-21. PubMed ID: 18575200
[TBL] [Abstract][Full Text] [Related]
25. Current management challenges in HIV: antiretroviral resistance.
Kuritzkes DR; Boyle BA; Gallant JE; Squires KE; Zolopa A
AIDS Read; 2003 Mar; 13(3):133-5, 138-42. PubMed ID: 12728868
[TBL] [Abstract][Full Text] [Related]
26. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.
Kandathil AJ; Kannangai R; Verghese VP; Pulimood SA; Rupali P; Sridharan G; Grant P; Pillay D; Abraham OC
Indian J Med Microbiol; 2009; 27(3):231-6. PubMed ID: 19584504
[TBL] [Abstract][Full Text] [Related]
27. Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia.
Abegaz WE; Grossman Z; Wolday D; Ram D; Kaplan J; Sibide K; Wuhib T; Ismael S; Nkengasong J; Mekonen T; Berhanu H; Messele T; Lulseged S; Maayan S; Mengistu Y
Antivir Ther; 2008; 13 Suppl 2():89-94. PubMed ID: 18575196
[TBL] [Abstract][Full Text] [Related]
28. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.
Canducci F; Sampaolo M; Marinozzi MC; Boeri E; Spagnuolo V; Galli A; Castagna A; Lazzarin A; Clementi M; Gianotti N
AIDS; 2009 Feb; 23(4):455-60. PubMed ID: 19165083
[TBL] [Abstract][Full Text] [Related]
29. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance.
Bennett DE; Bertagnolio S; Sutherland D; Gilks CF
Antivir Ther; 2008; 13 Suppl 2():1-13. PubMed ID: 18578063
[TBL] [Abstract][Full Text] [Related]
30. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
Tambuyzer L; Azijn H; Rimsky LT; Vingerhoets J; Lecocq P; Kraus G; Picchio G; de Béthune MP
Antivir Ther; 2009; 14(1):103-9. PubMed ID: 19320243
[TBL] [Abstract][Full Text] [Related]
31. Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.
Nijhuis M; Wensing AM; Bierman WF; de Jong D; Kagan R; Fun A; Jaspers CA; Schurink KA; van Agtmael MA; Boucher CA
J Infect Dis; 2009 Sep; 200(5):698-709. PubMed ID: 19627247
[TBL] [Abstract][Full Text] [Related]
32. [AIDS treatment in Africa: the risk of antiretroviral resistance].
Hamers RL; Schuurman R; van Vugt M; Derdelinckx I; Rinke de Wit TF
Ned Tijdschr Geneeskd; 2007 Dec; 151(48):2666-71. PubMed ID: 18179083
[TBL] [Abstract][Full Text] [Related]
33. Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania.
Somi GR; Kibuka T; Diallo K; Tuhuma T; Bennett DE; Yang C; Kagoma C; Lyamuya EF; Swai RO; Kassim S
Antivir Ther; 2008; 13 Suppl 2():77-82. PubMed ID: 18575194
[TBL] [Abstract][Full Text] [Related]
34. Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.
Di Giambenedetto S; Zazzi M; Corsi P; Gonnelli A; Di Pietro M; Giacometti A; Almi P; Trezzi M; Boeri E; Gianotti N; Menzo S; Del Gobbo R; Francisci D; Nerli A; Galli L; De Luca A;
Antivir Ther; 2009; 14(3):359-69. PubMed ID: 19474470
[TBL] [Abstract][Full Text] [Related]
35. Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs.
Perno CF; Moyle G; Tsoukas C; Ratanasuwan W; Gatell J; Schechter M
J Med Virol; 2008 Apr; 80(4):565-76. PubMed ID: 18297706
[TBL] [Abstract][Full Text] [Related]
36. Developments in HIV treatments: strategies for success.
Piliero P
AIDS Read; 2004 Dec; 14(12):655-65. PubMed ID: 15619781
[TBL] [Abstract][Full Text] [Related]
37. [Saving on drugs, reducing side-effects. Treatment interruptions benefit acute and chronic HIV infected patients].
Jäger H
MMW Fortschr Med; 2002 Apr; 144 Suppl 1():8-11. PubMed ID: 12043085
[TBL] [Abstract][Full Text] [Related]
38. Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.
Bergroth T; Ekici H; Gisslén M; Loes SK; Goh LE; Freedman A; Lampe F; Johnson MA; Sönnerborg A
J Med Virol; 2009 Jan; 81(1):1-8. PubMed ID: 19031460
[TBL] [Abstract][Full Text] [Related]
39. Antiretroviral regimens for treatment-experienced patients with HIV-1 infection.
Lagnese M; Daar ES
Expert Opin Pharmacother; 2008 Apr; 9(5):687-700. PubMed ID: 18345948
[TBL] [Abstract][Full Text] [Related]
40. The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world.
Bennett DE
Curr Opin Infect Dis; 2006 Dec; 19(6):607-14. PubMed ID: 17075338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
